Telerehabilitation In The Home After Stroke

NCT06682429 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.

Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \[1\] TR and usual care; \[2\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.

Conditions

Interventions

DEVICE

Telerehabilitation

The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.

Sponsors & Collaborators

  • Moss Rehabilitation Research Institute

    collaborator OTHER
  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH
  • University of California, Los Angeles

    lead OTHER

Principal Investigators

  • Steven Cramer, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-22
Primary Completion
2029-06-30
Completion
2030-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682429 on ClinicalTrials.gov